Tsvagiridzo nyowani kubva kuChirangaridzo Sloan Kettering Cancer Center (MSK) inotungamirwa nachiremba oncologist Shari Goldfarb, MD, uye vaanoshanda navo, inoshuma zvakawanikwa zvakanaka zvekushandiswa kwemapiritsi eAddyi (flibanserin) muvarwere vekenza yemazamu pane endocrine therapy vari kutambura nekurapa- kana chirwere. - induced low libido. Parizvino pane kushomeka kwemaitiro ekurapa anobatsira evakadzi ava vanotambura neHypoactive Sexual Desire Disorder (HSDD), kana kurasikirwa kwe libido, uye zvinofungidzirwa kuti vanhu vanopfuura mamirioni e16.5 vanogara nekupfuura kurapwa kwegomarara muUnited States. Zvakawanikwa zvakaunzwa paMusangano Wepagore weThe International Society for the Study of Women's Sexual Health (ISSWSH).
Dr. Shari Goldfarb, chiremba wemazamu weoncologist kubva kuChirangaridzo Sloan Kettering Cancer Center uye muongorori mukuru wechidzidzo ichi akati, “Kusashanda zvakanaka pabonde ndechimwe chezvinhu zvinowanzoitika uye zvisingagadzirisiki pakurapwa pakati pevakadzi vanorarama negomarara. Sevaongorori, taida kuita ongororo yekubatsira kurapa yadzikira libido, chinova chiratidzo chinoshungurudza kuvakadzi pa endocrine therapy. Ichi chidzidzo chakaongorora kukanganisa kweflibanserin pakuderera kwe libido muvakadzi vane kenza yemazamu pane endocrine therapy. Mhedzisiro yekutanga iri kuvimbisa uye inoratidza kuti chidzidzo ichi chiri munzira yekusangana neyakafanotsanangurwa inogoneka magumo nevatori vechikamu vazhinji vachiratidza kubatsirwa kukuru kubva kuflibanserin. "
Chidzidzo chirikuenderera mberi ichi chichanyoresa vakadzi makumi matatu vane gomarara rezamu pa endocrine therapy avo vari kurwara neHSDD. Mhedzisiro yekutanga kubva kuvakadzi vekutanga ve30 vanopedza mavhiki makumi maviri nemana ekurapa kweflibanserin inoratidza kuti chidzidzo chiri munzira yekusangana nemhedzisiro yayo yekutanga yekugoneka, ne> 20% yevakadzi vanopedza 24-vhiki yekurapa nguva uye 70% vakarega kudzidza nekukurumidza nekuda kwe chiitiko chakashata, izvo zvese zvakaitika mukati memavhiki maviri ekutanga ekurapa. Zviitiko zvakashata zvaisanganisira dzungu, kushaya hope, kurara, uye kuda kurutsa. Hapana zviitiko zvakakomba zvakashata zvakaitika muchidzidzo. Mukuwedzera, vakadzi vazhinji vakashuma kuwedzera kwechishuwo chepabonde, kuwedzera nhamba yezviitiko zvinogutsa zvepabonde (SSEs) uye kuderera kwekutambudzika kwakabatana mushure memavhiki masere ekurapwa.
Cindy Eckert, CEO weSprout Pharmaceuticals akati, “Mwoyo wangu unoenda kune vanopona kenza yemazamu avo vanowanzo kunetseka nekuderera kwavo libido. Iyi mhedzisiro yenguva pfupi pakushandiswa kweflibanserin munharaunda iyi inokurudzira. Tinotenda Dr. Goldfarb naSloan Kettering nekuita tsvakiridzo iyi huru uye nekuigovana nevekurapa.
Kusvika panguva ino, hapana FDA-inotenderwa mishonga yevakadzi vane HSDD yechipiri kune kenza kana kurapwa kwayo, uye ichangobva kubudiswa Phase II chidzidzo chakawana kuti bupropion yakanga isinganyanyi kushanda kupfuura placebo mukuvandudza chido chepabonde kune vakadzi vanopona kenza. Asi, zvinofungidzirwa kuti 70% yevakadzi vakaonekwa vaine kenza yemazamu vanotaura kuti vane dambudziko repabonde; izvi zvinosanganisira kuvhiringika kwechido chebonde nekupindura pabonde. Muna Kukadzi 2018, iyo American Society of Clinical Oncology (ASCO) yakaburitsa nhungamiro inokurudzira "Kune vakadzi vane cancer vari kunetsekana nekupindura pabonde, kusanganisira chishuwo, kumutswa, kana orgasm, vanachiremba vanofanirwa kupa psychosocial uye / kana psychosexual kuraira. Kune vakadzi vane premenopausal vane HSDD, vanachiremba vanogona kupa zano flibanserin. Nhungamiro yacho inotiwo "pani yakacherechedza kuti flibanserin haina kuongororwa muvakadzi vane nhoroondo yegomarara kana vakadzi vanotora hormonal therapy, saka kuongororwa kwengozi / kubatsirwa kwemushonga uyu kuvakadzi vakaonekwa vaine cancer hakuna kujeka." Zvakawanikwa naDr. Goldfarb zvekudzidza zvinopa data nyowani kubatsira kuvhara gaka iri muruzivo rwekurapa.
